Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Nature Communications|May 9, 2022
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitorsTyler S Beyett, Ciric To, David E Heppner, et al.
ACS Medicinal Chemistry Letters|December 15, 2022
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)David E Heppner, Florian Wittlinger, Tyler S Beyett, et al.
Bioorganic & Medicinal Chemistry Letters|April 4, 2022
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLCThomas W Gero, David E Heppner, Tyler S Beyett, et al.
Cancer Research|February 12, 2022
A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung CancerJieun Son, Jaebong Jang, Tyler S Beyett, et al.
Journal of Medicinal Chemistry|October 20, 2021
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric SitesFlorian Wittlinger, David E Heppner, Ciric To, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775Zhengnian Li, Jie Jiang, Yaning Wang, et al.
Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 5, 2026
High-throughput protein target mapping enables accelerated bioactivity discovery for ToxCast and PFAS compoundsDiwen Yang, Xiaoyun Wang, Jiabao Liu, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2025
High-throughput protein target mapping enables accelerated bioactivity discovery for ToxCast and PFAS compoundsDiwen Yang, Xiaoyun Wang, Jiabao Liu, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Pageof 4